Announcements
- Humana Is First Commercial Payer to Address TMS Therapy Coverage for Adolescents
- NeuroStar® TMS Advances Treatment for Adolescents During Mental Health Awareness Month
- New Publication in Brain Stimulation Confirms Full TMS Treatment Course Is Vital
- NeuroStar® Advanced Therapy Receives FDA Clearance as a First-Line Add-On Treatment for Adolescents with Depression
- Neuronetics Announces 5-Year Exclusive Partnership with Transformations Care Network
- Neuronetics Launches Latest Evolution in its TrakStar® Patient Data Management System
- NeuroStar TMS Patient Access Expands Through Lucet Health Policy Update
- Neuronetics Receives 510(k) Clearance for NeuroSite™ Coil Placement Accessory
- NeuroStar TMS Receives Expanded Regulatory Approval in Japan
- NeuroStar Elevates Depression Treatment with Cutting-Edge Technology Advancements
More ▼
Key statistics
On Friday, Neuronetics Inc (NRC:DUS) closed at 2.24, 4.43% above its 52-week low of 2.15, set on May 15, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 2.24 |
---|---|
High | 2.24 |
Low | 2.24 |
Bid | 2.32 |
Offer | 2.48 |
Previous close | 2.24 |
Average volume | 200.00 |
---|---|
Shares outstanding | 30.00m |
Free float | 28.10m |
P/E (TTM) | -- |
Market cap | 78.29m USD |
EPS (TTM) | -0.9484 USD |
Data delayed at least 15 minutes, as of May 17 2024 07:13 BST.
More ▼